We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

436 hedge funds and large institutions have $5.76B invested in Teva Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 127 increasing their positions, 135 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

42% more capital invested

Capital invested by funds: $4.07B → $5.76B (+$1.69B)

33% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 58

2% more funds holding

Funds holding: 427 → 436 (+9)

0.32% less ownership

Funds ownership: 54.15% → 53.83% (-0.32%)

6% less repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 135

40% less call options, than puts

Call options by funds: $354M | Put options by funds: $586M

Holders
436
Holders Change
+9
Holders Change %
+2.11%
% of All Funds
8.59%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.1%
New
77
Increased
127
Reduced
135
Closed
58
Calls
$354M
Puts
$586M
Net Calls
-$232M
Net Calls Change
-$65.6M

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$75M
2
MIFH
Migdal Insurance & Financial Holdings
Israel
+$73.7M
3
HIIFS
Harel Insurance Investments & Financial Services
Israel
+$47.7M
4
Two Sigma Investments
Two Sigma Investments
New York
+$21.3M
5
JP Morgan Chase
JP Morgan Chase
New York
+$18.8M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$192M
2
Renaissance Technologies
Renaissance Technologies
New York
-$42M
3
CS
Credit Suisse
Switzerland
-$36.1M
4
Jane Street
Jane Street
New York
-$26.1M
5
CI
Clal Insurance
Israel
-$22.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
376
Financial Perspectives
Minnesota
$2.99K +$2.72K +305 New
BFEC
377
Benjamin F. Edwards & Company
Missouri
$2K -$2.68K -300 -55%
GI
378
Gradient Investments
Minnesota
$2K -$384 -43 -18%
BRC
379
Bell Rock Capital
Delaware
$2K – – –
ClearBridge Investments
380
ClearBridge Investments
New York
$2K – – –
EWM
381
Edge Wealth Management
New York
$2K – – –
EIP
382
Ellis Investment Partners
Pennsylvania
$2K – – –
FHA
383
Flagship Harbor Advisors
Massachusetts
$2K – – –
FRA
384
Front Row Advisors
California
$2K – – –
GCM
385
Gables Capital Management
Florida
$2K – – –
JWA
386
JFS Wealth Advisors
Pennsylvania
$2K – – –
PFSC
387
Peoples Financial Services Corp
Pennsylvania
$2K – – –
PK
388
Pflug Koory
Nebraska
$2K – – –
TI
389
Truehand Inc
New Hampshire
$2K – – –
TFGT
390
TS Financial Group (TSFG)
Illinois
$2K – – –
WCM
391
Wealthcare Capital Management
Virginia
$2K +$1.56K +175 New
SIAS
392
Shine Investment Advisory Services
Colorado
$2K +$1.81K +203 New
TFA
393
Tobias Financial Advisors
Florida
$2K +$1.95K +218 New
TWP
394
TFO Wealth Partners
Ohio
$2K +$2.54K +285 New
KFS
395
Kelly Financial Services
Massachusetts
$1.47K – – –
WAP
396
Wealthcare Advisory Partners
Pennsylvania
$1K -$1.64K -184 -61%
BHWM
397
Bay Harbor Wealth Management
Maryland
$1K – – –
EARNEST Partners
398
EARNEST Partners
Georgia
$1K – – –
EWM
399
Endurance Wealth Management
Rhode Island
$1K – – –
FMII
400
Farmers & Merchants Investments Inc
Nebraska
$1K – – –
14 15
16
17 18

TEVA Hedge Fund Activity: Q4 2019 in Review

436 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2019, worth a combined $5.76B — up 42% from $4.07B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new TEVA positions and 58 closed out — a net gain of 19 holders — while 127 added to existing stakes and 135 trimmed.

The largest buyer was Menora Mivtachim Holdings, opening a new position worth an estimated $75M. The largest seller was Franklin Resources, cutting an estimated $192M.

  • 436 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2019, up from 427 in Q3 2019.
  • Funds reported $5.76B of Teva Pharmaceuticals stock for Q4 2019, up 42% quarter-over-quarter.
  • 77 funds opened new Teva Pharmaceuticals positions in Q4 2019 and 58 closed out, a net change of +19 holders.
  • The largest Teva Pharmaceuticals buyer in Q4 2019 was Menora Mivtachim Holdings, an estimated $75M added.
  • The largest Teva Pharmaceuticals seller in Q4 2019 was Franklin Resources, an estimated $192M sold.

Based on aggregated 13F filings for Q4 2019.